BTL Surpasses One Million EMFACE Treatments with 70% Growth in Record Q1, Launches First Non-invasive Treatment to Reverse Under-Eye Aging

MARLBOROUGH, Mass., April 8, 2025 /PRNewswire/ -- BTL, a global leader in medical and aesthetic innovation, announces the launch of EMFACE® Eye, the first non-invasive procedure designed to reverse under-eye aging by restoring muscle tone and soft tissue support at its foundation.

This launch comes as EMFACE surpasses one million treatments globally, making it the fastest-growing facial aesthetic technology to date. It follows a record-breaking Q1 2025, with 70% sales growth in North America, underscoring the momentum behind the brand and its cutting-edge portfolio.

"The response to EMFACE has been phenomenal," said David Chmel, CEO of BTL Industries. "Reaching the one million treatment mark and reporting our strongest Q1 in history is a testament to the power of BTL innovation - and the trust our providers place in us. With EMFACE Eye, we're once again pushing the boundaries of what's possible in non-invasive aesthetics."

EMFACE Eye addresses one of the most delicate, and previously hard-to-treat, areas: under-eye region. While traditional approaches have often relied on injectables or surgery to reduce puffiness, dark circles, and hollowness, EMFACE Eye offers a breakthrough complement. It tones the lower orbicularis oculi muscle, lifts soft tissue, and enhances periorbital support.

In a quick 20-minute, needle-free procedure, patients experience an average reduction of 1.4mL in eye bag volume, a 28% reduction in crow's feet, and a 64% decrease in dark circles. These clinically backed results require no downtime, making it a breakthrough for both providers and patients alike.

Dr. Melanie Palm, M.D., MBA, a respected cosmetic dermatologist in Solana Beach, CA, praised the advancement:

"As a cosmetic dermatologist with a sizeable injectable practice, this is exactly what I've been waiting for. The results include noticeable brightening of the under-eye and buttressing of the infraorbital fat pad, significantly reducing fat pseudo-herniation."

"Emface restores structure and function to the facial anatomy in the most natural way, so we can count on superior results that drive high patient satisfaction."

With the addition of Eye applicators, the EMFACE platform now enables full-face balancing across all anatomical thirds—from forehead lifting to jawline sculpting to under-eye enhancement. The platform supports a comprehensive, layered approach that pairs seamlessly with injectable treatments to deliver natural, harmonious result. 

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.

For more information, visit www.bodybybtl.com.

Media Contact – [email protected]

SOURCE BTL